Naveen Pemmaraju receives the IACH 2024 Special Achievement Award

The 7th Annual Meeting of the International Academy for Clinical Hematology (IACH), featuring the COMydAL, COLYM, and MPNCo&D tracks, is organized by CME Congresses Ltd. The event took place from September 19 to 21, 2024, at the Pullman Paris Tour Eiffel in Paris, Ile-de-France, France.

Naveen Pemmaraju received the IACH International Academy for Clinical Hematology (IACH) 2024 Special Achievement Award.

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

Naveen Pemmaraju shared a post on LinkedIn, regarding this:

“Today, I was honored to receive the prestgious IACH International Academy for Clinical Hematology (IACH) 2024 Special Achievement Award!

Thank you to Prof. Mohamad Mohty and Prof. Arnon Nagler and the entire IACH team for their continued support and recognition of my work in hashtag BPDCN and MPN.

Speical Thanks Prof. Leukemia Department – Hagop Kantarjian, M.D. and Mary E. Silverstein and Department of Leukemia MD Anderson Cancer Center for all of their long-time career support.

Thanks to my co-moderators/co-founders for the MPNCo&D track of IACH Prof. Ruben Mesa, MD and Prof. Claire Harrison for their support in MPNSM!”

The International Academy for Clinical Hematology (IACH) was established by a global group of physicians dedicated to advancing best practices in the field of clinical hematology.

More posts featuring Naveen Pemmaraju on oncodaily.com